797 related articles for article (PubMed ID: 27009503)
1. Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study.
Hatz K; Prünte C
Acta Ophthalmol; 2017 Feb; 95(1):e67-e72. PubMed ID: 27009503
[TBL] [Abstract][Full Text] [Related]
2. Switching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degeneration.
Kvannli L; Krohn J
Acta Ophthalmol; 2017 Nov; 95(7):678-682. PubMed ID: 28139082
[TBL] [Abstract][Full Text] [Related]
3. Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration.
Hatz K; Prünte C
Br J Ophthalmol; 2016 Oct; 100(10):1341-5. PubMed ID: 26755642
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Strategies of Treatment with Ranibizumab in Newly-Diagnosed Cases of Neovascular Age-Related Macular Degeneration.
Garweg JG; Niderprim SA; Russ HM; Pfister IB
J Ocul Pharmacol Ther; 2017 Dec; 33(10):773-778. PubMed ID: 28953427
[TBL] [Abstract][Full Text] [Related]
5. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
Ho AC; Busbee BG; Regillo CD; Wieland MR; Van Everen SA; Li Z; Rubio RG; Lai P;
Ophthalmology; 2014 Nov; 121(11):2181-92. PubMed ID: 25015215
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of a fixed bimonthly ranibizumab treatment regimen in eyes with neovascular age-related macular degeneration: results from the RABIMO trial.
Feltgen N; Bertelmann T; Bretag M; Pfeiffer S; Hilgers R; Callizo J; Goldammer L; Bemme S; Hoerauf H
Graefes Arch Clin Exp Ophthalmol; 2017 May; 255(5):923-934. PubMed ID: 28102456
[TBL] [Abstract][Full Text] [Related]
7. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study.
Spooner KL; Fraser-Bell S; Cozzi M; Staurenghi G; Invernizzi A; Monteduro D; Munk MR; Hong T; Chang AA
Ophthalmology; 2020 Dec; 127(12):1663-1673. PubMed ID: 32544561
[TBL] [Abstract][Full Text] [Related]
8. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration--a phase IV randomised clinical trial with ranibizumab: the FLUID study.
Arnold JJ; Markey CM; Kurstjens NP; Guymer RH
BMC Ophthalmol; 2016 Mar; 16():31. PubMed ID: 27009515
[TBL] [Abstract][Full Text] [Related]
9. Patterns of Early and Delayed Visual Response to Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration.
Stoller GL; Kokame GT; Dreyer RF; Shapiro H; Tuomi LL
JAMA Ophthalmol; 2016 May; 134(5):545-553. PubMed ID: 27010625
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Outcome in Patients with Neovascular Age-Related Macular Degeneration Switched from Ranibizumab to 8-Weekly Aflibercept.
Chatziralli I; Nicholson L; Vrizidou E; Koutsiouki C; Menon D; Sergentanis TN; Citu MC; Hamilton R; Patel PJ; Hykin P; Sivaprasad S
Ophthalmology; 2016 Aug; 123(8):1762-1770. PubMed ID: 27289179
[TBL] [Abstract][Full Text] [Related]
11. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
Li E; Donati S; Lindsley KB; Krzystolik MG; Virgili G
Cochrane Database Syst Rev; 2020 May; 5(5):CD012208. PubMed ID: 32374423
[TBL] [Abstract][Full Text] [Related]
12. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration.
Schmidt-Erfurth U; Waldstein SM; Deak GG; Kundi M; Simader C
Ophthalmology; 2015 Apr; 122(4):822-32. PubMed ID: 25578255
[TBL] [Abstract][Full Text] [Related]
13. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
Sadda SR; Tuomi LL; Ding B; Fung AE; Hopkins JJ
Ophthalmology; 2018 Jun; 125(6):878-886. PubMed ID: 29477692
[TBL] [Abstract][Full Text] [Related]
14. One-year outcome of ranibizumab for neovascular age-related macular degeneration: a thorough analysis in a real-world clinical setting.
Gabai A; Veritti D; Lanzetta P
Eur J Ophthalmol; 2014; 24(3):396-401. PubMed ID: 24242222
[TBL] [Abstract][Full Text] [Related]
15. Better visual outcome at 1 year with antivascular endothelial growth factor treatment according to treat-and-extend compared with pro re nata in eyes with neovascular age-related macular degeneration.
Aurell S; Sjövall K; Paul A; Morén Å; Granstam E
Acta Ophthalmol; 2019 Aug; 97(5):519-524. PubMed ID: 30511374
[TBL] [Abstract][Full Text] [Related]
16. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
[TBL] [Abstract][Full Text] [Related]
17. Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study.
Augsburger M; Sarra GM; Imesch P
Graefes Arch Clin Exp Ophthalmol; 2019 Sep; 257(9):1889-1895. PubMed ID: 31256237
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration.
Inoue M; Yamane S; Sato S; Sakamaki K; Arakawa A; Kadonosono K
Am J Ophthalmol; 2016 Sep; 169():95-103. PubMed ID: 27320059
[TBL] [Abstract][Full Text] [Related]
19. Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study.
Saenz-de-Viteri M; Recalde S; Fernandez-Robredo P; López Gálvez MI; Arias Barquet L; Figueroa MS; García-Arumí J; García-Layana A;
Acta Ophthalmol; 2021 Dec; 99(8):861-870. PubMed ID: 33720541
[TBL] [Abstract][Full Text] [Related]
20. Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease: One-Year Results of the Randomized Canadian Treat-and-Extend Analysis Trial with Ranibizumab Study.
Kertes PJ; Galic IJ; Greve M; Williams RG; Rampakakis E; Scarino A; Sheidow T
Ophthalmology; 2019 Jun; 126(6):841-848. PubMed ID: 30677465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]